Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman of Apoglyx, a Swedish biotech focused on aquaporins. Earlier in his career, he worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.
